title: The management of heart failure: a matter of definition?
abstract: The term heart failure has become a label for more than one clinical entity. For many years heart failure has been used to denote patients with various heart diseases who have begun to suffer from fluid retention, pulmonary venous hypertension, or systemic venous hypertension, either alone or in combination. More recently, the term heart failure has been applied to the combination of effort intolerance and reduced left ventricular contractility due to ischemic heart disease or other myocardial disease. Comparison of the results of epidemiological studies and therapeutic trials is complicated by variation in the composition of the patient populations selected for study. Drug treatment of heart failure remains fairly empirical. Distinction should be made between immediate or prognostic benefits related to the etiological diagnosis, and benefits related specifically to prevention and relief of, for example, fluid retention, rhythm disturbances, or ventricular hypertrophy. The response of individual patients to several forms of drug treatment, including digoxin, ACE inhibitors, and beta-blockade, is unpredictable. Prospective identification of patients liable to respond well to these drugs is not yet possible, but would greatly assist the choice of treatment. At present, trial of therapy is required in each patient to establish benefit and to avoid long-term treatment of nonresponders.
authors.affiliation: Cardiothoracic Centre-Liverpool NHS Trust, UK.
authors.forename: A
authors.initials: A
authors.lastname: Harley
mesh_terms: D002303:Cardiac Output, Low / Q000188:drug therapy / Q000628:therapy*; D002316:Cardiotonic Agents / Q000627:therapeutic use; D006801:Humans; D009626:Terminology as Topic
chemical_list: D002316:Cardiotonic Agents